Ji Xing buys Biogen’s acute ischemic stroke drug; Exelixis/BioInvent partnership ends; ClinChoice’s deal in SEA

Ji Xing ac­quires Bio­gen’s ex­per­i­men­tal ther­a­py for acute is­chemic stroke: The Shang­hai-based bio­phar­ma did not dis­close the fi­nan­cial terms of the deal. Back in 2018, Bio­gen li­censed the drug for $4 mil­lion up­front, with up to $335 mil­lion in mile­stones, be­fore ful­ly ac­quir­ing the as­set in 2021. — Jaimy Lee

BioIn­vent gets back rights to im­muno-on­col­o­gy tar­gets: Ex­elix­is is re­turn­ing the full rights to the Swedish biotech’s an­ti­bod­ies af­ter an­nounc­ing a re­struc­tur­ing ear­li­er this week. BioIn­vent said the tran­si­tion is ex­pect­ed to wrap up in the next 90 days. — Jaimy Lee

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.